title: Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.
authors.forename: S
authors.initials: S
authors.lastname: Nancey
authors.forename: G
authors.initials: G
authors.lastname: Boschetti
authors.forename: E
authors.initials: E
authors.lastname: Cotte
authors.forename: A
authors.initials: A
authors.lastname: Cathey-Javouhay
authors.forename: M
authors.initials: M
authors.lastname: Laidet
authors.forename: A
authors.initials: A
authors.lastname: Chichery
authors.forename: Y
authors.initials: Y
authors.lastname: Francois
authors.forename: O
authors.initials: O
authors.lastname: Glehen
authors.forename: B
authors.initials: B
authors.lastname: Flourié
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced* / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D011379:Prognosis; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000188:drug therapy; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab